MetaCap

Cytokinetics Incorporated Company Profile

NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

50.78-0.68 (-1.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Cytokinetics at a glance

Cytokinetics Incorporated (NASDAQ: CYTK) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in South San Francisco, CA. Cytokinetics is led by Mr. Robert I. Blum and employs about 673 people. The company's shares have traded publicly since 2004.

At a market capitalization of $7.17 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001061983, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Cytokinetics do?

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Business description based on the company's public filings.

Company information

Legal name
Cytokinetics Incorporated
Ticker
NASDAQ: CYTK
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Robert I. Blum
Employees
673
Headquarters
350 Oyster Point Boulevard, South San Francisco, CA, United States
Phone
650 624 3000
IPO year
2004
SEC CIK
0001061983

Companies similar to Cytokinetics

CYTK peer companies
CompanyPrice% ChgMarket capCompare
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs CYTK
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs CYTK
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs CYTK
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs CYTK
ALKSAlkermes plc44.94-2.69%$7.55Bvs CYTK
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs CYTK
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs CYTK
ABVXAbivax SA ADR73.20-9.24%$6.41Bvs CYTK

Related